# US 2021/0189357 A1 · Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0189357 A1
- Document ID: US20210189357A1
- Status: Published application
- Kind: A1
- Application number: 17/188,994
- Filed: 2021-03-01
- Published: 2021-06-24
- Earliest claimed: 2008-01-18
- Assignees: Biomarin Pharmaceutical Inc.
- Applicants: Biomarin Pharmaceutical Inc.
- Inventors: Erno Pungor; Charles Hague; Zhi Chen; Melita Dvorak-Ewell; Michel Claude Vellard; Vish Koppaka
- Web page: https://patentgrep.com/patent/US20210189357A1

## CPC

- C12N 9/16: acting on ester bonds (3.1)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 19/00: Drugs for skeletal disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- C12Q 1/34: involving hydrolase
- C12Q 1/44: involving esterase
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2267/035: Animal model for multifactorial diseases
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12Y 301/06014: N-Acetylglucosamine-6-sulfatase (3.1.6.14)
- G01N 2333/924: acting on glycosyl compounds (3.2)
- G01N 2400/40: Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2800/04: Endocrine or metabolic disorders
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.

## Claims

### Claim 1

A recombinant human lysosomal sulfatase enzyme or biologically active fragment, mutant, variant or derivative thereof produced in a END3 complementation group CHO cell or derivative thereof, wherein said END3 complementation group CHO cell or derivative thereof expresses recombinant human sulfatase modifying factor 1 (SUMF1), and wherein said recombinant lysosomal sulfatase enzyme or biologically active fragment, mutant, variant or derivative thereof has a high level of activation, and a high level of phosphorylation.

### Claim 2 (depends on 1)

The recombinant human lysosomal sulfatase enzyme or biologically active fragment, mutant, variant or derivative thereof of claim 1, wherein said recombinant lysosomal sulfatase enzyme is selected from the group consisting of arylsulfatase A (ARSA), arylsulfatase B (ARSB), iduronate-2-sulfatase (IDS), sulfamidase/heparin-N-sulfatase (SGSH), N-acetylglucosamine-sulfatase (G6S) and N-acetylgalactosamine-6-sulfatase (GALNS).

### Claim 3

A recombinant human N-acetylgalactosamine-6-sulfatase (GALNS) enzyme or biologically active fragment, mutant, variant or derivative thereof produced by a END3 complementation group CHO cell or derivative thereof, wherein said END3 complementation group CHO cell or derivative thereof expresses recombinant human sulfatase modifying factor 1 (SUMF1), and wherein said recombinant human GALNS has a high level of activation, and a high level of phosphorylation.

### Claim 4 (depends on 1, 2, 3)

The enzyme of any one of claims 1 to 3, wherein said END3 complementation group CHO cell or derivative thereof is a G71 cell line or G71 derivative.

### Claim 5

A method for producing an active highly phosphorylated recombinant human lysosomal sulfatase enzyme or biologically active fragment, mutant, variant or derivative thereof, comprising the steps of:
(a) culturing a Chinese Hamster Ovary (CHO)-derived END3 complementation group cell or derivative thereof;
(b) preparing a first mammalian expression vector capable of expressing said active highly phosphorylated recombinant human lysosomal sulfatase enzyme or biologically active fragment, mutant, variant or derivative thereof in said END3 complementation group cell or derivative thereof;
(c) preparing a second mammalian expression vector capable of expressing recombinant human sulfatase modifying factor 1 (SUMF1) or biologically active fragment, mutant, variant or derivative thereof in said END3 complementation group cell or derivative thereof;
(d) transfecting said END3 complementation group cell or derivative thereof with said first and second expression vectors;
(e) selecting and cloning of a transfectant of said END3 complementation group cell or derivative thereof that expresses said active highly phosphorylated recombinant human lysosomal sulfatase enzyme or biologically active fragment, mutant, variant or derivative thereof; and
(f) optimizing a cell culture process method for manufacturing said highly phosphorylated recombinant human lysosomal sulfatase enzyme or biologically active fragment, mutant, variant or derivative thereof,
wherein the recombinant human lysosomal sulfatase enzyme is selected from the group consisting of arylsulfatase A (ARSA), arylsulfatase B (ARSB), iduronate-2-sulfatase (IDS), sulfamidase/heparin-N-sulfatase (SGSH), N-acetylglucosamine-sulfatase (G6S) and N-acetylgalactosamine-6-sulfatase (GALNS).

### Claim 6 (depends on 5)

The method of claim 5, wherein said first and second expression vectors are transfected into said END3 complementation group cell or derivative thereof in step (d) simultaneously.

### Claim 7 (depends on 5)

The method of claim 5, wherein said first and second expression vectors are transfected into said END3 complementation group cell or derivative thereof in step (d) sequentially.

### Claim 8 (depends on 5, 6, 7)

The method of any one of claims 5 to 7, wherein the END3 complementation group CHO cell or derivative thereof is a G71 cell line or G71 derivative.

### Claim 9 (depends on 5, 6, 7, 8)

An active highly phosphorylated recombinant human lysosomal sulfatase enzyme or biologically active fragment, mutant, variant or derivative thereof produced by the method of any one of claims 5 to 8.

### Claim 10 (depends on 9)

A pharmaceutical composition comprising the lysosomal sulfatase enzyme or biologically active fragment, mutant, variant or derivative thereof of claim 9 and one or more pharmaceutically acceptable carriers, diluents or excipients.

### Claim 11

A method for producing an active highly phosphorylated recombinant human N-acetylgalactosamine-6-sulfatase (GALNS) enzyme or biologically active fragment, mutant, variant or derivative thereof or variant thereof, comprising the steps of:
(a) culturing a Chinese Hamster Ovary (CHO)-derived END3 complementation group cell or derivative thereof;
(b) preparing a first mammalian expression vector capable of expressing said active highly phosphorylated recombinant human GALNS or biologically active fragment, mutant, variant or derivative thereof suitable for said END3 complementation group cell or derivative thereof;
(c) preparing a second mammalian expression vector capable of expressing recombinant human sulfatase modifying factor 1 (SUMF1) or biologically active fragment, mutant, variant or derivative thereof suitable for said END3 complementation group cell or derivative thereof;
(d) transfecting said END3 complementation group cell or derivative thereof with said first and second expression vectors;
(e) selecting and cloning of a transfectant of said END3 complementation group cell or derivative thereof that expresses said active highly phosphorylated recombinant human GALNS or biologically active fragment, mutant, variant or derivative thereof; and
(f) optimizing a cell culture process method for manufacturing said active highly phosphorylated recombinant human GALNS or biologically active fragment, mutant, variant or derivative thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein said first and second expression vectors are transfected into said END3 complementation group cell or derivative thereof in step (d) simultaneously.

### Claim 13 (depends on 11)

The method of claim 11, wherein said first and second expression vectors are transfected into said END3 complementation group cell or derivative thereof in step (d) sequentially.

### Claim 14 (depends on 11, 12, 13)

The method of any one of claims 11 to 13 wherein the END3 complementation group CHO cell or derivative thereof is a G71 cell line or G71 derivative.

### Claim 15 (depends on 11, 12, 13, 14)

A highly active highly phosphorylated recombinant human N-acetylgalactosamine-6-sulfatase (GALNS) enzyme or biologically active fragment, mutant, variant or derivative thereof produced by the method of any one of claims 11 to 14.

### Claim 16 (depends on 15)

A pharmaceutical composition comprising the recombinant human N-acetylgalactosamine-6-sulfatase (GALNS) enzyme or biologically active fragment, mutant, variant or derivative thereof of claim 15 and one or pharmaceutically acceptable carriers, diluents or excipients.

### Claim 17

A recombinant human N-acetylgalactosamine-6-sulfatase (GALNS) enzyme or biologically active mutant, variant or derivative thereof useful for treating a subject suffering from a lysosomal storage disease that is caused by or associated with a deficiency in said GALNS, wherein said GALNS enzyme or biologically active mutant, variant or derivative thereof:
(a) has a purity of at least about 90% as determined by Coomassie Blue staining when subjected to SDS-PAGE under non-reducing conditions;
(b) has at least about 90% conversion of the cysteine residue at position 53 to Cα-formylglycine (FGly); and
(c) is N-linked glycosylated at the asparagine residues at positions 178 and 397, wherein at least about 50% of the oligomannose chains attached to the asparagine residue at position 178 are bis-phosphorylated.

### Claim 18 (depends on 17)

The GALNS enzyme of claim 17, wherein the lysosomal storage disease is Mucopolysaccharidosis type IVa (MPS IVa) or Morquio A syndrome.

### Claim 19 (depends on 17)

The GALNS enzyme of claim 17, wherein the lysosomal storage disease is Multiple Sulfatase Deficiency.

### Claim 20 (depends on 17)

The GALNS enzyme of claim 17, wherein the GALNS enzyme consists of a major band of about 55-60 kDa that is at least about 75% of the visible proteins as determined by Coomassie Blue staining when subjected to SDS-PAGE under reducing conditions.

### Claim 21 (depends on 17)

The GALNS enzyme of claim 17, wherein the GALNS enzyme consists essentially of a single band of about 55-60 kDa as determined by Coomassie Blue staining when subjected to SDS-PAGE under reducing conditions.

### Claim 22

A method of treating a subject suffering from a deficiency of a lysosomal sulfatase enzyme comprising administering to the subject in need of said lysosomal sulfatase enzyme a therapeutically effective amount of said lysosomal sulfatase enzyme, wherein said lysosomal sulfatase enzyme is a recombinant human lysosomal sulfatase enzyme or biologically active fragment, mutant, variant or derivative thereof produced by a CHO-derived END3 complementation group cell or a derivative thereof.

### Claim 23 (depends on 22)

The method of claim 22, wherein said lysosomal sulfatase enzyme deficiency is selected from the group consisting of Metachromatic Leukodystrophy (MLD), Mucopolysaccharidosis type VI (MPS VI) or Maroteaux-Lamy syndrome, Mucopolysaccharidosis type II (MPS II) or Hunter syndrome, Mucopolysaccharidosis type IIIa (MPS IIIa) or Sanfilippo A syndrome, Mucopolysaccharidosis type IIId (MPS IIId) or Sanfilippo D syndrome, and Mucopolysaccharidosis type IVa (MPS IVa) or Morquio A syndrome.

### Claim 24 (depends on 23)

The method of claim 23, wherein said lysosomal sulfatase enzyme deficiency is MPS IVa or Morquio A Syndrome.

### Claim 25

A method of treating a lysosomal storage disease that is associated with a deficiency in one or more lysosomal sulfatase enzymes, comprising administering to a subject having a deficiency in said one or more lysosomal sulfatase enzymes a therapeutically effective amount of recombinant human N-acetylgalactosamine-6-sulfatase (GALNS) enzyme or biologically active fragment, mutant, variant or derivative thereof produced by a CHO-derived END3 complementation group cell or a derivative thereof.

### Claim 26 (depends on 25)

The method of claim 25, wherein the lysosomal storage disease is Multiple Sulfatase Deficiency (MSD).

### Claim 27 (depends on 22, 23, 24, 25, 26)

The method of any one of claims 22 to 26, wherein the END3 complementation group CHO cell or derivative thereof is a G71 cell line or G71 derivative.

### Claim 28

A method of treating a subject suffering from Mucopolysaccharidosis type IVa (MPS IVa) or Morquio A syndrome, or Multiple Sulfatase Deficiency (MSD), comprising administering to the subject a therapeutically effective amount of a purified, recombinant human N-acetylgalactosamine-6-sulfatase (GALNS) enzyme or biologically active mutant, variant or derivative thereof, wherein said GALNS or biologically active mutant, variant or derivative thereof:
(a) has a purity of at least about 90% as determined by Coomassie Blue staining when subjected to SDS-PAGE under non-reducing conditions;
(b) has at least about 90% conversion of the cysteine residue at position 53 to Cα-formylglycine (FGly); and
(c) is N-linked glycosylated at the asparagine residues at positions 178 and 397, wherein at least about 50% of the oligomannose chains attached to the asparagine residue at position 178 are bis-phosphorylated.

### Claim 29 (depends on 28)

The method of claim 28, wherein the subject is suffering from MPS IVa or Morquio A syndrome.

### Claim 30 (depends on 28)

The method of claim 28, wherein the subject is suffering from MSD.

### Claim 31 (depends on 28)

The method of claim 28, wherein the GALNS enzyme consists of a major band of about 55-60 kDa that is at least about 75% of the visible proteins as determined by Coomassie Blue staining when subjected to SDS-PAGE under reducing conditions.

### Claim 32 (depends on 28)

The method of claim 28, wherein the GALNS enzyme consists essentially of a single band of about 55-60 kDa as determined by Coomassie Blue staining when subjected to SDS-PAGE under reducing conditions.

### Claim 33

An END3 complementation group CHO cell line derived from G71 or a derivative thereof, wherein the END3 complementation group CHO cell line comprises:
(a) an expression vector for recombinant human sulfatase modifying factor 1 (SUMF1); and
(b) an expression vector for a recombinant human lysosomal sulfatase enzyme, wherein the recombinant human lysosomal sulfatase enzyme is selected from the group consisting of arylsulfatase A (ARSA), arylsulfatase B (ARSB), iduronate-2-sulfatase (IDS), sulfamidase/heparin-N-sulfatase (SGSH), N-acetylglucosamine-sulfatase (G6S) and N-acetylgalactosamine-6-sulfatase (GALNS).

### Claim 34 (depends on 33)

The END3 complementation group CHO cell line of claim 33, wherein the END3 complementation group CHO cell line comprises the expression vector for recombinant human N-acetylgalactosamine-6-sulfatase (GALNS).

### Claim 35 (depends on 34)

The END3 complementation group CHO cell line of claim 34, wherein the END3 complementation group CHO cell line expresses and secretes recombinant human GALNS.

### Claim 36 (depends on 34)

The END3 complementation group CHO cell line of claim 34, wherein the END3 complementation group CHO cell line is selected from the group consisting of clone 4, clone 5, clone C6, clone C2, clone C5, clone C7, clone C10, clone C11 and clone C30.

### Claim 37 (depends on 34)

The END3 complementation group CHO cell line of claim 34, wherein the END3 complementation group CHO cell line is clone C2.

### Claim 38 (depends on 34)

The END3 complementation group CHO cell line of claim 34, wherein the END3 complementation group CHO cell line is adapted to growth in suspension.

### Claim 39

A method for measuring the activity of a recombinant human lysosomal enzyme to degrade natural substrates, comprising:
(a) culturing an isolated human cell deficient in the lysosomal enzyme under conditions in which natural substrates for the lysosomal enzyme accumulate;
(b) contacting the cell with the lysosomal enzyme;
(c) lysing the cell;
(d) adding to the cell lysate an enzyme that (i) is specific for natural substrates and (ii) cleaves small oligosaccharides from the natural substrates;
(e) labeling the small oligosaccharides with a detectable moiety;
(f) optionally separating the labeled small oligosaccharides;
(g) detecting the labeled small oligosaccharides; and
(h) determining the activity of the lysosomal enzyme to degrade natural substrates by comparing (i) the amount of labeled small oligosaccharides from cells contacted with the lysosomal enzyme with (ii) the amount of labeled small oligosaccharides from cells not contacted with the lysosomal enzyme,
wherein a reduction in (h)(i) as compared to (h)(ii) indicates the activity of the lysosomal enzyme to degrade natural substrates.

### Claim 40 (depends on 39)

The method of claim 39, wherein the lysosomal enzyme is a lysosomal sulfatase enzyme selected from the group consisting of arylsulfatase B (ARSB), iduronate-2-sulfatase (IDS), sulfamidase/heparin-N-sulfatase (SGSH), N-acetylglucosamine-sulfatase (G6S) and N-acetylgalactosamine-6-sulfatase (GALNS).

### Claim 41 (depends on 40)

The method of claim 40, wherein the lysosomal sulfatase enzyme is GALNS.

### Claim 42 (depends on 39)

The method of claim 39, wherein the lysosomal enzyme is α-L-iduronidase (IDU).
